Yubo International Biotech Ltd
YBGJOTCHealthcare · Electromedical & Electrotherapeutic Apparatus · NY · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $12,353 | $3,470 | $604,676 | $104,283 | $1.2M | $0 |
| Operating income | −$1.2M | −$1.8M | −$1.2M | −$1.2M | −$1.5M | −$711,798 |
| Net income | −$1.1M | −$1.8M | −$1.2M | −$1.2M | −$1.5M | −$711,801 |
| Total assets | $847,094 | $1.5M | $1.7M | $2.3M | $4.6M | $2.4M |
| Total liabilities | $2.8M | $4.8M | $3.5M | $2.9M | $4.7M | $1.3M |
| Equity | −$2.0M | −$3.4M | −$1.8M | −$565,373 | −$131,198 | $1.2M |
| EPS (diluted) | $-0.01 | $-0.02 | $-0.10 | — | — | — |
| Shares out. | 119.8M | 119.8M | 119.8M | 118.2M | — | 1.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −9614.6%
- Net margin
- −8736.7%
- Return on equity
- 55.2%
- Return on assets
- −127.4%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 329.5%
- Debt / equity
- —
- Book value / share
- $-0.02
- Revenue growth (YoY)
- 256.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -56.39distress
- Accruals / assets
- −27.9%clean
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 13, 2024
- NT 10-Qmissed a reporting deadline ↗May 13, 2024
- NT 10-Kmissed a reporting deadline ↗Mar 28, 2024
- NT 10-Qmissed a reporting deadline ↗Nov 13, 2023
- NT 10-Kmissed a reporting deadline ↗Mar 28, 2023
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2022
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Chinaone Technology LtdActivist (13D)Jul 25, 2025
- Flydragon International LtdActivist (13D)Jul 25, 2025
- Boao Biotech LtdPassive (13G)Jun 3, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 114 | 1000.0 | 0.0% |
| Apr 30, 2026 | 114 | 1.0 | 0.0% |
| Apr 15, 2026 | 114 | 1.0 | 0.0% |
| Mar 31, 2026 | 114 | 1000.0 | 0.0% |
| Mar 13, 2026 | 114 | 1.0 | 0.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Changed auditorJan 16, 2026
- Entered a material agreement · Unregistered equity saleJul 25, 2025
- Changed auditorJan 6, 2025
- Regulation FD disclosure · Other material eventNov 10, 2022
- Entered a material agreementSep 9, 2022
- Amended charter or bylawsApr 13, 2021
- Amended charter or bylawsFeb 5, 2021
- Entered a material agreement · Completed an acquisition or disposition · Unregistered equity sale · Item 5.06Jan 14, 2021
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-QFORM 10-QMay 15, 2026
- 10-KFORM 10-KMar 31, 2026
- 8-KFORM 8-KJan 16, 2026
- 10-QFORM 10-QNov 14, 2025
- 10-QFORM 10-QAug 13, 2025
- 4FORM 4Jul 25, 2025
- 4FORM 4Jul 25, 2025
- SCHEDULE 13D/AJul 25, 2025
- SCHEDULE 13D/AJul 25, 2025
- 8-KFORM 8-KJul 25, 2025
- SCHEDULE 13GJun 3, 2025
- 4FORM 4Jun 3, 2025
- 4FORM 4Jun 2, 2025
- 10-QFORM 10-QMay 14, 2025
- 3FORM 3May 5, 2025
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.